Boryung secure exclusive rights to sell nano-particle anticancer drug developed by SN Bioscience

[Courtesy of Boryung Pharmaceutical]

SEOUL -- Boryung Pharmaceutical has secured exclusive rights to sell 'SNB-101, a nano-particle anticancer drug developed by SN Bioscience, for 10 years after its release in South Korea. Discussion is also under way to sell the drug in Asian countries.

SN-38 is a potent active metabolite of irinotecan with a wide range of anti-tumor effects, but it has extremely low solubility in biological fluids. SN Bioscience, a nano-medicine research and development company in South Korea, has developed a stable and safe SN-38 nano-particle injection called "SNB-101" with approved biopolymers by "double core-shell micelle" technology.

Combined with chemo-cancer drugs, targeted anti-cancer drugs, and radiation treatments, SNB-101 has a higher anti-tumor effect than the single treatment of existing treatments, SN Bioscience said. Phase I clinical trials began in November 2020. "Through this contract, we have secured the possibility of SNB-101 entering domestic and global markets," SN Bioscience CEO Park Young-hwan said, adding SNB-101 showed good results in preclinical tests.

Lim Chang-won cwlim34@ajunews.com

Boryung secure exclusive rights to sell nano-particle anticancer drug developed by SN Bioscience

Related